2026 Global: Ai-Based Clinical Trials-Competitive Review (2032) report
Description
The 2026 Global: Ai-Based Clinical Trials-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for ai-based clinical trials by geography and historical trend. The scope of the report extends to sizing of the ai-based clinical trials market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Unlearn.ai, Saama, and Antidote Technologies lead the AI-based clinical trials landscape, leveraging machine learning for trial optimization, patient matching, and data analytics. Unlearn.ai pioneers digital twins to simulate patient outcomes, reducing placebo needs and accelerating trials, as seen in partnerships with Roche. Saama, awarded Best AI-Based Solution for Life Sciences in 2024, integrates real-time analytics to cut timelines and boost success rates through data-driven insights. Antidote Technologies streamlines recruitment with AI algorithms matching patient profiles to trials, enhancing efficiency and lowering costs amid rising demand for faster processes. Phesi’s Trial Accelerator, incorporating data from over 100 million patients by 2024, enables precise simulations for better design and recruitment. Deep6.ai and Innoplexus further innovate; Deep6.ai automates site selection and enrollment, while Innoplexus, via 2024 EDDC collaboration, accelerates drug indications using AI platforms.
Medidata, IQVIA, and BenevolentAI dominate with comprehensive AI ecosystems for end-to-end trial management. Medidata applies AI to data synthesis and analysis, addressing challenges in therapy development for time and cost savings. IQVIA, a CRO giant, deploys its Orchestrated Clinical Trials platform with AI for protocol optimization, EHR integration, and 20% timeline reductions across global hybrid trials. BenevolentAI focuses on drug discovery integration into trials, enhancing biomarker identification and decision-making. Clario deploys AI, ML, and deep learning over 1,600 times for endpoint analysis and scalable data processing. Intelligencia AI provides actionable insights from trial data, fostering competition and adoption in optimization.
ICON plc, Insitro, and Unlearn.ai exemplify pharma-tech synergy, with ICON’s AI Assistant earning 2025 awards for adaptive trials and Firecrest platform enabling remote management. Insitro advances ML-driven trial workflows in precision medicine. These ten companies—Unlearn.ai, Saama, Antidote, Phesi, Deep6.ai, Innoplexus, Medidata, IQVIA, BenevolentAI, and ICON—drive a market projected to grow via partnerships like Eli Lilly-Medable for decentralized recruitment and AstraZeneca-Immunai for cancer optimizations, reducing durations by 25% and improving outcomes. Their tools automate recruitment, predict endpoints, and integrate real-world evidence, transforming trials into efficient, patient-centric processes amid 30% partnership rises from 2022-2024.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for ai-based clinical trials by geography and historical trend. The scope of the report extends to sizing of the ai-based clinical trials market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Unlearn.ai, Saama, and Antidote Technologies lead the AI-based clinical trials landscape, leveraging machine learning for trial optimization, patient matching, and data analytics. Unlearn.ai pioneers digital twins to simulate patient outcomes, reducing placebo needs and accelerating trials, as seen in partnerships with Roche. Saama, awarded Best AI-Based Solution for Life Sciences in 2024, integrates real-time analytics to cut timelines and boost success rates through data-driven insights. Antidote Technologies streamlines recruitment with AI algorithms matching patient profiles to trials, enhancing efficiency and lowering costs amid rising demand for faster processes. Phesi’s Trial Accelerator, incorporating data from over 100 million patients by 2024, enables precise simulations for better design and recruitment. Deep6.ai and Innoplexus further innovate; Deep6.ai automates site selection and enrollment, while Innoplexus, via 2024 EDDC collaboration, accelerates drug indications using AI platforms.
Medidata, IQVIA, and BenevolentAI dominate with comprehensive AI ecosystems for end-to-end trial management. Medidata applies AI to data synthesis and analysis, addressing challenges in therapy development for time and cost savings. IQVIA, a CRO giant, deploys its Orchestrated Clinical Trials platform with AI for protocol optimization, EHR integration, and 20% timeline reductions across global hybrid trials. BenevolentAI focuses on drug discovery integration into trials, enhancing biomarker identification and decision-making. Clario deploys AI, ML, and deep learning over 1,600 times for endpoint analysis and scalable data processing. Intelligencia AI provides actionable insights from trial data, fostering competition and adoption in optimization.
ICON plc, Insitro, and Unlearn.ai exemplify pharma-tech synergy, with ICON’s AI Assistant earning 2025 awards for adaptive trials and Firecrest platform enabling remote management. Insitro advances ML-driven trial workflows in precision medicine. These ten companies—Unlearn.ai, Saama, Antidote, Phesi, Deep6.ai, Innoplexus, Medidata, IQVIA, BenevolentAI, and ICON—drive a market projected to grow via partnerships like Eli Lilly-Medable for decentralized recruitment and AstraZeneca-Immunai for cancer optimizations, reducing durations by 25% and improving outcomes. Their tools automate recruitment, predict endpoints, and integrate real-world evidence, transforming trials into efficient, patient-centric processes amid 30% partnership rises from 2022-2024.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.